UNSPSC 51284000: Tetracyclines

This classification denotes closely congeneric derivatives of the polycyclic naphthacenecarboxamide, and naphthacene antibiotics that inhibits amino acyl trna binding during protein synthesis, a four-ringed cyclic compound, TETRA-CYCLINE, TETRAC-YCLINES, and TETRACYCLINE antibiotics.

UNSPSC 51284000 Tetracyclines is a Class code that does not align with the state and local procurement activity currently tagged under it. The recent opportunities show no purchases of tetracycline antibiotics or related pharmaceutical compounds. Instead, the opportunities tagged to this code span emergency medical supplies (naloxone and drug deactivation systems), pharmacy benefit program design, generic multi-source pharmaceuticals, and first-aid consumables for fire rescue operations. The mismatch suggests either miscoding of opportunities at the point of posting or a fundamental disconnect between the code's pharmaceutical scope and how jurisdictions are labeling their health-related purchasing activity. State and local governments do buy pharmaceuticals and medical supplies in volume, but the tetracycline code itself shows little decision-relevant recent activity under its nominal scope.

The few recent opportunities present span Florida, Texas, and Minnesota through mixed issuing bodies: Seminole County (Florida) for naloxone and drug deactivation kits via an IFB due July 26, 2023; the Texas Health and Human Services Commission for direct-to-manufacturer pharmacy program strategy via an RFI with an April 3, 2026 response date; the City of Tampa for medical and first-aid supplies for fire rescue via an IFB due March 13, 2026, with an estimated contract value of $700,000 and an SLBE set-aside with a 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic pharmaceuticals and OTC products via an RFP due March 26, 2026, covering multiple states including Oregon. Without recent, properly coded activity in the tetracycline category itself, pursuing opportunities under this code requires first confirming with issuing bodies whether tetracycline-specific procurement is planned or whether pharmaceutical activity will continue to be miscoded to this category.